Details for Patent: 8,193,196
Which drugs does patent 8,193,196 protect, and when does it expire?
Patent 8,193,196 protects XIFAXAN and is included in one NDA.
This patent has thirty-four patent family members in twenty-six countries.
Summary for Patent: 8,193,196
| Title: | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
| Abstract: | Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. |
| Inventor(s): | Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Miriam Barbanti, Dario Braga |
| Assignee: | Alfasigma SpA |
| Application Number: | US11/658,702 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,193,196 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; Dosage form; |
Drugs Protected by US Patent 8,193,196
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-001 | May 25, 2004 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-002 | Mar 24, 2010 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF | ⤷ Start Trial | |
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-002 | Mar 24, 2010 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS | ⤷ Start Trial | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,193,196
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 05004695 | Mar 03, 2005 | |
| PCT Information | |||
| PCT Filed | February 27, 2006 | PCT Application Number: | PCT/EP2006/001755 |
| PCT Publication Date: | September 14, 2006 | PCT Publication Number: | WO2006/094662 |
International Family Members for US Patent 8,193,196
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006222312 | ⤷ Start Trial | |||
| Brazil | PI0608073 | ⤷ Start Trial | |||
| Canada | 2594789 | ⤷ Start Trial | |||
| China | 1900077 | ⤷ Start Trial | |||
| Denmark | 1698630 | ⤷ Start Trial | |||
| European Patent Office | 1698630 | ⤷ Start Trial | |||
| Spain | 2522895 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
